Portage Biotech Inc (PTGEF) 0.1050 $PTGEF
Portage Announces Orphan Drug Designation Request Granted to Biohaven for BHV-4157
PR Newswire - Wed May 25, 8:24AM CDT
FDA Grants Biohaven Orphan Drug Designation for BHV-4157 for the Treatment of Patients with Spinocerebellar Ataxia (SCA)
Portage announces the appointment of Chief Commercial Officer at Biohaven
PR Newswire - Wed Apr 27, 8:00AM CDT
Portage Biotech Inc. ("Portage"
(OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that Biohaven Pharmaceutical Holding Company Limited (Biohaven) has appointed John Tilton as Chief Commercial Officer. Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. where he was an Executive Director and one of the founding commercial leaders responsible for the commercialization of multiple orphan drug indications. Mr. Tilton played a central role in the successful global launches of Soliris, as well as building operational infrastructure, for four orphan indication launches in over 30 countries for Alexion.
ALXN: 153.89 (-2.88)
Portage announcing results of its Annual Shareholder Meeting and other corporate matters
PR Newswire - Thu Apr 07, 8:10AM CDT
Portage Biotech Inc. ("Portage" or "the Company" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce the election of Steven Mintz to the Board of Directors at the Company's Annual and Special Meeting of Shareholders ("ASM" held on April 6, 2016. Mr. Mintz has been a Chartered Accountant since 1992 and received his BA (Economics and Accounting) from the University of Toronto in 1989. He obtained his Trustee in Bankruptcy license in 1995 and C.A. designation in June of 1992. From 1992 to 1997 he was employed by a boutique bankruptcy and insolvency firm and from 1989 until 1992 he did public accounting at a large accounting firm. Since January 1997 he has been a self-employed financial consultant serving both private individuals and companies as well as public companies in a variety of industries including mining, oil and gas, real estate and investment strategies. He has been a director of two CPCs, which have completed Qualifying Transactions. He has been, and currently is, an officer and director of several publicly traded companies. Mr. Mintz will hold office as a director until the next annual meeting. It is anticipated that Mr. Mintz will be appointed to the Corporation's audit committee and will qualify as an independent member in accordance with National Instrument 52-110 Audit Committees.
Portage's further investment in Biohaven
PR Newswire - Wed Mar 23, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that Biohaven Pharmaceutical Holding Company Limited ("Biohaven" recently raised approximately $ 3 million at a price of $3,500 per its common share. Portage subscribed for $ 1,001,000 and an independent director of Biohaven subscribed for the balance.
Portage Announces Proposed Private Placement
PR Newswire - Fri Mar 11, 8:00AM CST
Portage Biotech Inc. ("Portage" or "the Company" (OTC: PTGEF, Canadian Securities Exchange: PBT.U), announces that it intends to conduct a Private Placement to raise up to US$ 2 million for funding its development activities and finance clinical activities at Biohaven Pharmaceutical Holding Company Limited, ("Biohaven" .
Portage's Biohaven orphan drug designation request granted for the treatment of spinocerebellar ataxia
PR Newswire - Thu Mar 03, 12:26PM CST
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), are pleased to announce that the Food and Drug Administration ("FDA" has granted the company's orphan drug designation request covering BHV-0223 for the treatment of spinocerebellar ataxia. Spinocerebellar ataxia (SCA) is characterized clinically by progressive ataxia attributed to various etiologies. Ataxia is a complaint of loss of control of voluntary body movements and can involve unsteady gait, speech difficulties, and clumsiness, potentially progressing to the stage of difficulty with swallowing and breathing due to degenerative changes in the brain and spinal cord. There is no cure for the hereditary SCAs and lifespan can be significantly shortened due to complications related to neurologic deficits. It is estimated that 150,000 people in the United States are affected by hereditary ataxias. Treatment is supportive and no medications are currently approved for this potentially debilitating condition.
Portage Issues Letter to Shareholders
PR Newswire - Fri Jan 15, 9:03AM CST
Portage Biotech Inc. ("Portage" or "the Company" ) (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), released a Letter to Shareholders today. A copy of the letter can be found on our web site at http://portagebiotech.com/news/letter-to-shar...-chairman/
Portage's Biohaven announces Phase 1 pharmacokinetic study meets study objectives and supports advancing BHV-0223 and also appoints a CEO
PR Newswire - Thu Nov 19, 3:30PM CST
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today that preliminary results from a Phase I study with BHV-0223, a glutamate modulating agent, met its study objectives and supports advancing the asset into late phase clinical development. BHV-0223 is a unique formulation of a glutamate modulating agent that utilizes the Zydis® ODT fast-dissolve technology under an exclusive worldwide agreement with Catalent. Agents that modulate glutamate neurotransmission may have therapeutic potential in multiple glutamatergically driven disease states including amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Rett syndrome, dementia, dystonia, tinnitus, anxiety disorders, and numerous affective disorders like GAD and OCD.
Portage's Biohaven Completes Multiple Dose Phase of Pharmacokinetic Trial with BHV-0223
PR Newswire - Tue Oct 06, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today that Biohaven has completed the multiple dose portion of the Phase I study with BHV-0223, a glutamate modulating agent. Biohaven filed an investigational drug application (IND) regarding BHV-0223 and obtained clearance from the U.S. Food and Drug Administration (FDA) to proceed with human testing. Portage holds 54% equity interest in Biohaven, a private company.
Biohaven and Fox Chase Chemical Diversity Center Announce Strategic Alliance in Early Stage Drug Discovery Research
PR Newswire - Thu Oct 01, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), are pleased to announce a strategic alliance with ALS Biopharma LLC ("ALS" and Fox Chase Chemical Diversity Center, Inc. (FCCDC) to develop Biohaven's family of over 300 prodrugs of glutamate modulating agents as well as other innovative technologies. Under this agreement, Biohaven will provide $1.5M in research funding to FCCDC to advance a lead prodrug candidate to IND filing.
JNJ: 114.76 (+0.27), MRK: 56.64 (-0.18)
Portage's Biohaven Completes Single Dose Phase of Pharmacokinetic Trial with BHV-0223
PR Newswire - Mon Sep 21, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today that Biohaven has completed the single dose portion of its Phase I study of BHV-0223, a glutamate modulating agent. This summer, Biohaven filed an investigational drug application (IND) regarding BHV-0223 and obtained clearance from the U.S. Food and Drug Administration (FDA) to proceed with human testing. Portage holds 54% equity interest in Biohaven, a private company.
Portage's Biohaven's lead drug candidate clears FDA Investigational New Drug Application (IND) review and clinical studies to begin
PR Newswire - Mon Aug 24, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U) and Biohaven Pharmaceutical Holding Company Limited ("Biohaven" are pleased to announce that the United States Food and Drug Administration has completed its review of Biohaven's Investigational New Drug Application (IND) for BHV-0223 and initial clinical studies in humans may begin. Portage holds 54% equity interest in Biohaven.
Portage's Biohaven Acquires Intellectual Property for Portfolio of Prodrugs from ALS Biopharma, LLC
PR Newswire - Tue Aug 18, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U) and Biohaven Pharmaceutical Holding Company Limited ("Biohaven" are pleased to announce that Biohaven has acquired the world-wide intellectual property rights to a portfolio of over 300 prodrugs owned by ALS Biopharma, LLC ("ALSBio" . The prodrugs covered by the agreement were designed and prepared by Fox Chase Chemical Diversity Center, Inc. ("FCCDC" through a research program funded, in part, by the U.S. National Institutes of Health, through two peer-reviewed Small Business Innovation Research (SBIR) grants awarded to FCCDC. Most of the ALSBio prodrugs would be classified as New Molecular Entities (NMEs), and the intellectual property rights acquired by Biohaven include all future therapeutic indications.
Portage Invests in Sentien Biotechnologies Inc.
PR Newswire - Mon Aug 10, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company" (Canadian Securities Exchange: PBT.U, OTC Markets : PTGEF), is pleased to announce that it has made a Series A investment in Sentien Biotechnologies Inc.("Sentien" , a Medford, MA based regenerative medicine company. Portage is joined in this round of investment by Boehringer Ingelheim Venture Fund USA, Inc. ("BIVF" . Sentien will use the proceeds of its Series A round to fund its activities through a planned Phase I study of their lead product, the Sentinel(TM), a cell-containing dialysis device for the treatment of Acute Kidney Injury (AKI).
Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing
PR Newswire - Thu Jul 23, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), are pleased to announce that Biohaven has filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) to conduct clinical testing of BHV-0223. Portage holds 54% equity interest in Biohaven, a private company.
Portage Completes Non-brokered Private Placement in Two Tranches for a Total Proceeds of US$ 5,155,080
PR Newswire - Thu Jun 25, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company" (Canadian Securities Exchange: PBT.U , OTC Markets : PTGEF,), is pleased to announce that it has completed its non-brokered private placement raising US$5,155,080 through issuance of approximately 36.8 million common shares at US$0.14 each. The private placement was completed in two tranches, first tranche closed on June 15, 2015 as per our press release of June 16, 2015 and second and final tranche closed on June 24, 2015. The Company is debt free. Total number of common shares issued and outstanding after this private placement are 245,438,890.
Portage Closes First Tranche of Private Placement
PR Newswire - Tue Jun 16, 3:52PM CDT
Portage Biotech Inc. ("Portage" or "the Company" (OTC: PTGEF, Canadian Securities Exchange: PBT.U), announces that it has raised approximately $3.4 million by closing the first tranche of the non-brokered Private Placement previously announced on May 19, 2015. Pursuant to the terms of the private placement, Portage issued 23,881,214 common shares at a price of US$0.14 per share. All shares issued under private placement are subject to statutory hold periods. Two of the directors of the Company, Dr. Bailey and Mr. Mellon subscribed US$ 800,000 each.
Portage Biotech Announces Non-Brokered Private Placement - Video News Alert on InvestmentPitch.com
Newsfile Corp - Thu May 21, 10:08AM CDT
full story)
Portage's Biohaven to begin Phase 1 study in 3Q2015 and readying for Phase 3 study start by 1Q2016
PR Newswire - Wed Apr 22, 10:00AM CDT
Biohaven to Initiate Pharmacokinetic and Biomarker Study with Lead Drug Development Candidate in 3Q2015
Portage Announces Orphan Drug Designation Request Granted to Biohaven for BHV-4157
PR Newswire - Wed May 25, 8:24AM CDT
FDA Grants Biohaven Orphan Drug Designation for BHV-4157 for the Treatment of Patients with Spinocerebellar Ataxia (SCA)
Portage announces the appointment of Chief Commercial Officer at Biohaven
PR Newswire - Wed Apr 27, 8:00AM CDT
Portage Biotech Inc. ("Portage"
(OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that Biohaven Pharmaceutical Holding Company Limited (Biohaven) has appointed John Tilton as Chief Commercial Officer. Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. where he was an Executive Director and one of the founding commercial leaders responsible for the commercialization of multiple orphan drug indications. Mr. Tilton played a central role in the successful global launches of Soliris, as well as building operational infrastructure, for four orphan indication launches in over 30 countries for Alexion. ALXN: 153.89 (-2.88)
Portage announcing results of its Annual Shareholder Meeting and other corporate matters
PR Newswire - Thu Apr 07, 8:10AM CDT
Portage Biotech Inc. ("Portage" or "the Company"
(OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce the election of Steven Mintz to the Board of Directors at the Company's Annual and Special Meeting of Shareholders ("ASM" held on April 6, 2016. Mr. Mintz has been a Chartered Accountant since 1992 and received his BA (Economics and Accounting) from the University of Toronto in 1989. He obtained his Trustee in Bankruptcy license in 1995 and C.A. designation in June of 1992. From 1992 to 1997 he was employed by a boutique bankruptcy and insolvency firm and from 1989 until 1992 he did public accounting at a large accounting firm. Since January 1997 he has been a self-employed financial consultant serving both private individuals and companies as well as public companies in a variety of industries including mining, oil and gas, real estate and investment strategies. He has been a director of two CPCs, which have completed Qualifying Transactions. He has been, and currently is, an officer and director of several publicly traded companies. Mr. Mintz will hold office as a director until the next annual meeting. It is anticipated that Mr. Mintz will be appointed to the Corporation's audit committee and will qualify as an independent member in accordance with National Instrument 52-110 Audit Committees. Portage's further investment in Biohaven
PR Newswire - Wed Mar 23, 8:00AM CDT
Portage Biotech Inc. ("Portage"
(OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that Biohaven Pharmaceutical Holding Company Limited ("Biohaven" recently raised approximately $ 3 million at a price of $3,500 per its common share. Portage subscribed for $ 1,001,000 and an independent director of Biohaven subscribed for the balance. Portage Announces Proposed Private Placement
PR Newswire - Fri Mar 11, 8:00AM CST
Portage Biotech Inc. ("Portage" or "the Company"
(OTC: PTGEF, Canadian Securities Exchange: PBT.U), announces that it intends to conduct a Private Placement to raise up to US$ 2 million for funding its development activities and finance clinical activities at Biohaven Pharmaceutical Holding Company Limited, ("Biohaven" . Portage's Biohaven orphan drug designation request granted for the treatment of spinocerebellar ataxia
PR Newswire - Thu Mar 03, 12:26PM CST
Portage Biotech Inc. ("Portage"
(OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), are pleased to announce that the Food and Drug Administration ("FDA" has granted the company's orphan drug designation request covering BHV-0223 for the treatment of spinocerebellar ataxia. Spinocerebellar ataxia (SCA) is characterized clinically by progressive ataxia attributed to various etiologies. Ataxia is a complaint of loss of control of voluntary body movements and can involve unsteady gait, speech difficulties, and clumsiness, potentially progressing to the stage of difficulty with swallowing and breathing due to degenerative changes in the brain and spinal cord. There is no cure for the hereditary SCAs and lifespan can be significantly shortened due to complications related to neurologic deficits. It is estimated that 150,000 people in the United States are affected by hereditary ataxias. Treatment is supportive and no medications are currently approved for this potentially debilitating condition. Portage Issues Letter to Shareholders
PR Newswire - Fri Jan 15, 9:03AM CST
Portage Biotech Inc. ("Portage" or "the Company"
) (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), released a Letter to Shareholders today. A copy of the letter can be found on our web site at http://portagebiotech.com/news/letter-to-shar...-chairman/ Portage's Biohaven announces Phase 1 pharmacokinetic study meets study objectives and supports advancing BHV-0223 and also appoints a CEO
PR Newswire - Thu Nov 19, 3:30PM CST
Portage Biotech Inc. ("Portage"
(OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today that preliminary results from a Phase I study with BHV-0223, a glutamate modulating agent, met its study objectives and supports advancing the asset into late phase clinical development. BHV-0223 is a unique formulation of a glutamate modulating agent that utilizes the Zydis® ODT fast-dissolve technology under an exclusive worldwide agreement with Catalent. Agents that modulate glutamate neurotransmission may have therapeutic potential in multiple glutamatergically driven disease states including amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Rett syndrome, dementia, dystonia, tinnitus, anxiety disorders, and numerous affective disorders like GAD and OCD. Portage's Biohaven Completes Multiple Dose Phase of Pharmacokinetic Trial with BHV-0223
PR Newswire - Tue Oct 06, 8:00AM CDT
Portage Biotech Inc. ("Portage"
(OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today that Biohaven has completed the multiple dose portion of the Phase I study with BHV-0223, a glutamate modulating agent. Biohaven filed an investigational drug application (IND) regarding BHV-0223 and obtained clearance from the U.S. Food and Drug Administration (FDA) to proceed with human testing. Portage holds 54% equity interest in Biohaven, a private company. Biohaven and Fox Chase Chemical Diversity Center Announce Strategic Alliance in Early Stage Drug Discovery Research
PR Newswire - Thu Oct 01, 8:00AM CDT
Portage Biotech Inc. ("Portage"
(OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), are pleased to announce a strategic alliance with ALS Biopharma LLC ("ALS" and Fox Chase Chemical Diversity Center, Inc. (FCCDC) to develop Biohaven's family of over 300 prodrugs of glutamate modulating agents as well as other innovative technologies. Under this agreement, Biohaven will provide $1.5M in research funding to FCCDC to advance a lead prodrug candidate to IND filing. JNJ: 114.76 (+0.27), MRK: 56.64 (-0.18)
Portage's Biohaven Completes Single Dose Phase of Pharmacokinetic Trial with BHV-0223
PR Newswire - Mon Sep 21, 8:00AM CDT
Portage Biotech Inc. ("Portage"
(OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today that Biohaven has completed the single dose portion of its Phase I study of BHV-0223, a glutamate modulating agent. This summer, Biohaven filed an investigational drug application (IND) regarding BHV-0223 and obtained clearance from the U.S. Food and Drug Administration (FDA) to proceed with human testing. Portage holds 54% equity interest in Biohaven, a private company. Portage's Biohaven's lead drug candidate clears FDA Investigational New Drug Application (IND) review and clinical studies to begin
PR Newswire - Mon Aug 24, 8:00AM CDT
Portage Biotech Inc. ("Portage"
(OTC Market: PTGEF, Canadian Securities Exchange: PBT.U) and Biohaven Pharmaceutical Holding Company Limited ("Biohaven" are pleased to announce that the United States Food and Drug Administration has completed its review of Biohaven's Investigational New Drug Application (IND) for BHV-0223 and initial clinical studies in humans may begin. Portage holds 54% equity interest in Biohaven. Portage's Biohaven Acquires Intellectual Property for Portfolio of Prodrugs from ALS Biopharma, LLC
PR Newswire - Tue Aug 18, 8:00AM CDT
Portage Biotech Inc. ("Portage"
(OTC Market: PTGEF, Canadian Securities Exchange: PBT.U) and Biohaven Pharmaceutical Holding Company Limited ("Biohaven" are pleased to announce that Biohaven has acquired the world-wide intellectual property rights to a portfolio of over 300 prodrugs owned by ALS Biopharma, LLC ("ALSBio" . The prodrugs covered by the agreement were designed and prepared by Fox Chase Chemical Diversity Center, Inc. ("FCCDC" through a research program funded, in part, by the U.S. National Institutes of Health, through two peer-reviewed Small Business Innovation Research (SBIR) grants awarded to FCCDC. Most of the ALSBio prodrugs would be classified as New Molecular Entities (NMEs), and the intellectual property rights acquired by Biohaven include all future therapeutic indications. Portage Invests in Sentien Biotechnologies Inc.
PR Newswire - Mon Aug 10, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company"
(Canadian Securities Exchange: PBT.U, OTC Markets : PTGEF), is pleased to announce that it has made a Series A investment in Sentien Biotechnologies Inc.("Sentien" , a Medford, MA based regenerative medicine company. Portage is joined in this round of investment by Boehringer Ingelheim Venture Fund USA, Inc. ("BIVF" . Sentien will use the proceeds of its Series A round to fund its activities through a planned Phase I study of their lead product, the Sentinel(TM), a cell-containing dialysis device for the treatment of Acute Kidney Injury (AKI). Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing
PR Newswire - Thu Jul 23, 8:00AM CDT
Portage Biotech Inc. ("Portage"
(OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), are pleased to announce that Biohaven has filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) to conduct clinical testing of BHV-0223. Portage holds 54% equity interest in Biohaven, a private company. Portage Completes Non-brokered Private Placement in Two Tranches for a Total Proceeds of US$ 5,155,080
PR Newswire - Thu Jun 25, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company"
(Canadian Securities Exchange: PBT.U , OTC Markets : PTGEF,), is pleased to announce that it has completed its non-brokered private placement raising US$5,155,080 through issuance of approximately 36.8 million common shares at US$0.14 each. The private placement was completed in two tranches, first tranche closed on June 15, 2015 as per our press release of June 16, 2015 and second and final tranche closed on June 24, 2015. The Company is debt free. Total number of common shares issued and outstanding after this private placement are 245,438,890. Portage Closes First Tranche of Private Placement
PR Newswire - Tue Jun 16, 3:52PM CDT
Portage Biotech Inc. ("Portage" or "the Company"
(OTC: PTGEF, Canadian Securities Exchange: PBT.U), announces that it has raised approximately $3.4 million by closing the first tranche of the non-brokered Private Placement previously announced on May 19, 2015. Pursuant to the terms of the private placement, Portage issued 23,881,214 common shares at a price of US$0.14 per share. All shares issued under private placement are subject to statutory hold periods. Two of the directors of the Company, Dr. Bailey and Mr. Mellon subscribed US$ 800,000 each. Portage Biotech Announces Non-Brokered Private Placement - Video News Alert on InvestmentPitch.com
Newsfile Corp - Thu May 21, 10:08AM CDT
full story)
Portage's Biohaven to begin Phase 1 study in 3Q2015 and readying for Phase 3 study start by 1Q2016
PR Newswire - Wed Apr 22, 10:00AM CDT
Biohaven to Initiate Pharmacokinetic and Biomarker Study with Lead Drug Development Candidate in 3Q2015
